History
2002: The Research & Development laboratories of Caffaro Srl-SNIA Group with the experience and expertise of many decades of chemical process research of one of the most important Italian chemical companies, becomes an independent business unit under the name Serichim and offers the chemical companies its services as CRO.
2005: In May 2005 SERICHIM celebrates the opening of the new laboratory completely renovated with an investment of about 3 million Euro. The event is attended by personalities of the Italian and European chemical world such as Prof. Renato Ugo and Dr. Peter Pollack.
2006: In March 2006 with an MBO, Pietro Delogu and Fausto Ferrazzi, with the support of other public and private partners, acquire the R&D branch of Caffaro; SERICHIM to become the first independent Italian chemical contract research organization (CRO). SERICHIM can count on important skills for research in the chemical, chemical-pharmaceutical and agrochemical sectors, in the field of environmental research and also in the study of new technologies for the development of continuous processes.
2007: In May SERICHIM, with the DD 740 / Ric., achieve the endorsement of Italian Ministry of Education as a highly qualified chemical research lab and in September the endorsement of region Friuli Venezia Giulia. In October, adheres to IT-SusChem, Italian branch of EPT-SusChem, the European platform for the development of a sustainable chemistry.
In December SERICHIM achieved the expected results inthe first project financed by the Friuli Venezia Giulia for the development of mini- and micro technologies applied to the synthesis of intermediates and pharmaceutical products.
2008: The development of know-how for the use of residues of animal fats and vegetable oils with high acidity content as raw materials for the production of biodiesel, made in collaboration with the University of Urbino, is finalized. It makes these raw materials viable alternatives to the use of raw materials for food uses. An original continuous process for the synthesis of D,L-Homocysteic acid is used for the small-scale production of the product.
2009: Completion of the study of an innovative chemical process suitable to eliminate mercury pollution from river and marine sediments is successfully tested on sediments of the lagoon of Grado and Marano and other polluted areas.
2010: Filed a patent on a continuous process for the production of Gabapentin.
2011: Among the research contracts concluded during the year of particular importance is the development of new synthetic pathways for CA monomers made on request of a multinational company, world leader in its industrial segment.
2012: The end of the development of a proprietary technology of a multi-functional continuous reactor and the Compact Chem ™ patent is filed.
2013: Successful testing of the Compact Chem ™ technology for the polymerization of acrylic polymers.
2014: At the end of October is completed all the objectives the pilot testing of an innovative process for the recovery of metals from industrial waste that exploits wet oxidation technology. An innovative process for the production of paracyclophane is developed on behalf of an industrial partner.
In July starts the project called "The Chemistry of Formulations for Made in Italy: new technology platforms for eco-leather and fabrics" funded by Mi.S.E. SERICHIM leads a partnership of 18 players including private corporations, universities and CNR.
2018: Technology transfer agreement with the International Center for Genetic Engineering and Biotechnology of Triest, Italy for a biosimilars drug development pipeline.
2019: Formation of the Biotechnology Department with the addition of 3 new scientist. The expertise in molecular and cellular biology, protein biochemistry, industrial fermentation, bioprocess engineering, protein synthesis, microbiology testing strategies and microbiological quality controls complements to the chemical expertise in-house.
2020: Installation of both the new HPLC-MS X500R QTOF SCIEX mass spectrometry for state-of -the-art analyses and the new biotechnology production laboratory.
2021: BMGPharma SpA settles in part of the SERICHIM laboratories with the aim of exploiting the synergies present on the site for its development program of innovative products based on modified hyaluronic acids.
2022: SERICHIM acquires the Torviscosa buildings from Caffaro Srl in AS and Biovalley Investment Partners consolidates its participation with a dedicated capital increase. The share capital is 642,500 thousand euros.
2022: in collaboration with two important industrial groups, a project for a plant for the capture of CO2 and its transformation into pharmaceutical grade bicarbonate is successfully concluded.
In collaboration with Bracco Imaging and the University of Udine, a patent is filed for an innovative synthesis of a raw material molecule for a new contrast medium for RNM diagnostics.
2023: the development of the first biosimilar of the market-leading slow-release insulin analogue whose patent expires in 2027 is concluded and gathers the interest of some operators. Negotiations begin for the transfer of the technology license and of the supply of reagents used.
SERICHIM files a patent application for the Dynamic Hydrogen Dispenser (DHR) which, based on LHOHC (liquid organic hydrogen carriers) technology, is part of the projects aimed at facilitating the development of hydrogen as a clean energy carrier.
2024: Clean Energy Srl acquires some shares of SERICHIM with the aim of contributing to the development of projects related to Hydrogen use for green mobility and as energy vector in multiple sectors.